## Abstract Lamivudine therapy often causes breakthrough of hepatitis B virus (HBV) DNA and breakthrough hepatitis. The aim of this study was to determine the viral factors that relate to HBVβDNA breakthrough with and without breakthrough hepatitis. Among 82 patients with chronic hepatitis B (CHB)
Kinetics of HBV DNA and HBsAg in acute hepatitis B patients with and without coinfection by other hepatitis viruses
β Scribed by Vladimir P. Chulanov; German A. Shipulin; Stephan Schaefer; Wolfram H. Gerlich
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 221 KB
- Volume
- 69
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
The kinetics of hepatitis B virus (HBV) and its surface antigen (HBsAg) during acute hepatitis has not yet been studied accurately in a representative number of patients. The influence of coinfecting hepatitis viruses during the acute phase of infection is not known. Three to four serum samples from 21 patients with acute HBV monoinfection and 27 with coinfection were taken at intervals of 6β10 days and analyzed for the number of HBV genome equivalents (ge) by real time polymerase chain reaction (PCR) and for HBsAg quantity using Laurell electrophoresis. Log HBV ge/ml decreased during the followβup from 6.8βΒ±β1.1 to 5.1βΒ±β1.0 to 4.2βΒ±β0.8 to 3.3βΒ±β1.1 (meanβΒ±βSD). The halfβlife times of HBV ge increased from 1.6 days at the beginning to 4 days at the end. HBsAg decreased much slower: from 38 to 23 to 12 to3.8 ΞΌg/ml. Halfβlife time was around 8 days at the beginning and 5.7 days at the end, but 11 patients showed a rapid elimination of HBsAg and HBV DNA. Hepatitis C virus (HCV) coinfection did not change the kinetics of HBV ge and HBsAg significantly. A moderate but significant suppression of HBV ge levels was observed in hepatitis D virus (HDV) coinfected patients. HBsAg levels were, however, enhanced in this cohort. In conclusion, the data suggest that expression and elimination of HBV is in most patients with acute hepatitis B not altered by coinfecting hepatitis viruses. The initial decrease of HBV ge and HBsAg in serum appears to be caused by decay or nonβspecific removal in the absence of replacement. J. Med. Virol. 69:313β323, 2003. Β© 2003 WileyβLiss, Inc.
π SIMILAR VOLUMES
No data are available about the amount of hepatitis B virus (HBV) genomes in liver of patients with chronic HBV infection. The aim of this study was to quantify the intrahepatic HBV DNA in hepatitis B surface antigen (HBsAg)-positive patients with either active or suppressed viral replication and in
Sera from 79 patients with acute self-limiting hepatitis, 17 patients with acute hepatitis B evolving into chronic HBsAg carriership, and 43 chronic HBsAg carriers without a history of acute hepatitis were analyzed for presence of hepatitis B virus (HBV)-DNA by a molecular hybridization technique. I
The aim of the study was to investigate whether an ''inapparent'' coinfection by hepatitis B virus (HBV) in anti-HCV-positive chronic liver disease patients may influence interferon (IFN) response. Fourteen anti-HCV-positive, hepatitis B surface antigen (HBsAg)-negative but serum HBV-DNA-positive pa
Acute exacerbation (AE) of chronic hepatitis B is usually preceded by reemergence or increase of hepatitis B virus (HBV) in the serum. To investigate the origin of the reemergence or increase, we compared the identity of the serum viral genome to that in the liver and in previous AE by full-length s
To evaluate the clinical implication of IgM antibody against hepatitis B core antigen (anti-HBc IgM), a consecutive series of 87 patients with acute type B hepatitis and 16 healthy carriers of hepatitis B surface antigen (HBsAg) were studied by a newly developed reverse ELISA technique. Anti-HBc Ig